Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis

NYU Langone Health75 enrolled

Overview

This study will examine the efficacy of combined nebulized hypertonic saline with chest percussion therapy in patients age 0 to 24 months admitted to the general inpatient pediatrics unit with acute bronchiolitis. 3% nebulized hypertonic saline treatments combined with 3 minutes of chest percussion therapy will be administered every 6 hours of patients selected for the study.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Bronchiolitis

Interventions

Nebulized 3% sodium chloride solutionDRUG

Standardized dose of nebulized 3% sodium chloride will be provided from 4 mL vial and administered be every 6 hours.

Chest percussion cupsDEVICE

The chest percussion cup is a small, flexible cup made of vinyl that is used to provide gentle chest wall vibrations to assist with airway clearance and is utilized in patients of all ages with sputum production, such as those with acute bronchiolitis. Administered every 6 hours while on supplemental oxygen therapy.

Eligibility

Sex: ALLMin age: 0 MonthsMax age: 24 Months

Medical Language ↔ Plain English

Inclusion Criteria: In order to be eligible to participate in this study (experimental arm), an individual must meet all of the following criteria: * Age 0 to 24 months * Admitted to the general inpatient pediatrics unit * Has a diagnosis of acute bronchiolitis * Receiving supplemental oxygen support Data collected for the control arm will be obtained via retrospective chart review for patients meeting the following inclusion criteria: * Age 0 to 24 months * Admitted to the general inpatient pediatrics unit * Has a diagnosis of acute bronchiolitis * Receiving supplemental oxygen support Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Admitted to the pediatric intensive care unit * Has an underlying pre-existing condition that may affect the respiratory system (includes bronchopulmonary dysplasia, reactive airways disease, asthma, restrictive lung diseases, other chronic lung diseases, etc.) * Has other comorbid conditions upon admission that may affect the respiratory system (includes pneumonia or other bacterial or fungal lung infections, acute exacerbation of reactive airways disease, acute exacerbation of asthma, pulmonary edema, pleural effusion, etc.) * Has an absolute contraindication to nebulized 3% hypertonic saline, for example, a history of an allergic or anaphylactic reaction * Is receiving other respiratory treatments such as bronchodilator treatments (i.e. albuterol or levalbuterol) * Is receiving other adjuvant therapy such as antibiotics, antivirals, glucocorticoids, corticosteroids, or diuretics A potential study subject in the control arm via retrospective chart review who meets any of the following criteria will be excluded from this study: * Admitted to the pediatric intensive care unit * Has an underlying pre-existing condition that may affect the respiratory system (includes bronchopulmonary dysplasia, reactive airways disease, asthma, restrictive lung diseases, other chronic lung diseases, etc.) * Has other comorbid conditions upon admission that may affect the respiratory system (includes pneumonia or other bacterial or fungal lung infections, acute exacerbation of reactive airways disease, acute exacerbation of asthma, pulmonary edema, pleural effusion, etc.) * Has an absolute contraindication to nebulized 3% hypertonic saline, for example, a history of an allergic or anaphylactic reaction * Is receiving other respiratory treatments such as bronchodilator treatments (i.e. albuterol or levalbuterol) * Is receiving other adjuvant therapy such as antibiotics, antivirals, glucocorticoids, corticosteroids, or diuretics

Locations (1)

NYU Langone Health

Mineola, New York, United States

Outcomes

Primary Outcomes

Length of Hospital Stay

Measured in days from from time of admission to the general inpatient pediatrics unit until time of discharge from the general inpatient pediatrics unit.